Novonesis shares are up more than six percent since this morning after the company raised its guidance. The biotech company now expects organic growth in 2025 to be between seven and eight percent. Previously, the expectation was for organic growth between six and eight percent.
This is evident from Novonesis' third-quarter financial statements, which were published on Thursday morning. In the third quarter, Novonesis had revenue of just over one billion euros, or 7.9 billion kroner.
According to the financial statements, this corresponds to organic growth of six percent when compared to the same quarter a year earlier. Earnings in the third quarter amounted to 138 million euros compared to 155.7 million euros in 2024.
/ritzau/
Text, graphics, images, sound, and other content on this website are protected under copyright law. DK Medier reserves all rights to the content, including the right to exploit the content for the purpose of text and data mining, cf. Section 11b of the Copyright Act and Article 4 of the DSM Directive.
Customers with IP agreements/major customer agreements may only share Danish Offshore Industry articles internally for the purpose of handling specific cases. Sharing in connection with specific cases refers to journaling, archiving, or similar uses.
Customers with a personal subscription/login may not share Danish Offshore Industry articles with individuals who do not themselves have a personal subscription to Danish Offshore Industry.
Any deviation from the above requires written consent from DK Medier.
